Adaptimmune Therapeutics PLC | Business Contracts

Termination and Transfer Agreement made and effective as of April 6, 2023 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on April 11, 2023)

Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 5, 2023, by and among Adaptimmune Therapeutics plc, CM Merger Sub, Inc. and TCR (Filed With SEC on April 5, 2023)

Form of Voting and Support Agreement, dated as of March 5, 2023, by and among Adaptimmune, TCR2 and certain shareholders of Adaptimmune (Filed With SEC on March 6, 2023)

Separation and Consulting Agreement dated as of March 3, 2023 by and between Adaptimmune, LLC and Cintia Piccina and effective as of March 5, 2023 (Filed With SEC on March 6, 2023)

Form of Voting and Support Agreement, dated as of March 5, 2023, by and among Adaptimmune, TCR2 and certain stockholders of TCR2 (Filed With SEC on March 6, 2023)

Agreement and Plan of Merger, dated as of March 5, 2023, by and among Adaptimmune, CM Merger Sub, Inc. and TCR2 (Filed With SEC on March 6, 2023)

Description of the Registrants Securities (Filed With SEC on March 6, 2023)

Letter of Appointment dated February 15, 2023 between Adaptimmune Therapeutics plc and Kristen Hege and effective from November 1, 2023 (Filed With SEC on February 16, 2023)

Amendment Agreement No. 8 made and effective as of December 19, 2022 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on December 20, 2022)

Deed of Variation dated June 15, 2022, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited and Adaptimmune Limited relating to a lease of 39 Innovation Drive,... (Filed With SEC on June 15, 2022)

Deed of Surrender of Part dated June 15, 2022, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited and Adaptimmune Limited relating to a lease of 39... (Filed With SEC on June 15, 2022)

Employment Agreement dated as of May 4, 2022 by and between Adaptimmune Limited and Joanna Brewer (Filed With SEC on May 4, 2022)

Description of the Registrants Securities (Filed With SEC on March 14, 2022)

Employment Agreement dated as of January 26, 2022 by and between Adaptimmune, LLC and Cintia Piccina (Filed With SEC on January 26, 2022)

Rent Security Deposit Deed dated August 20, 2021, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited, Adaptimmune Limited and Adaptimmune Therapeutics plc... (Filed With SEC on August 20, 2021)

Deed of Variation dated August 20, 2021, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited and Adaptimmune Limited relating to a lease of 39 Innovation... (Filed With SEC on August 20, 2021)

Agreement dated August 13, 2021, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited, Adaptimmune Limited and Adaptimmune Therapeutics plc relating to 39... (Filed With SEC on August 13, 2021)

Deed of Variation dated August 13, 2021, between MEPC Milton Park No 1 Limited and MEPC Milton Park No. 2 Limited, Adaptimmune Limited and Adaptimmune Therapeutics plc relating to... (Filed With SEC on August 13, 2021)

Description of the Registrants Securities (Filed With SEC on February 25, 2021)

Employment Agreement dated as of December 16, 2020 by and between Adaptimmune, LLC and Elliot Norry (Filed With SEC on December 16, 2020)

Underwriting Agreement, dated June 1, 2020, by and among Adaptimmune Therapeutics plc, Cowen and Company, LLC and SVB Leerink LLC, as representative of the several Underwriters... (Filed With SEC on June 2, 2020)

Description of the Registrants Securities (Filed With SEC on February 27, 2020)

Collaboration and License Agreement, dated January 13, 2020, by and between Universal Cells, Inc. and Adaptimmune Limited (Filed With SEC on February 27, 2020)

Variation Agreement dated as of February 17, 2020 by and between La Fosse Associates Limited, GAR-1 Business Advisory Services and Adaptimmune, LLC (Filed With SEC on February 18, 2020)

Variation Agreement dated as of February 17, 2020 by and between Adaptimmune, LLC and La Fosse Associates Limited (Filed With SEC on February 18, 2020)

Service Agreement dated as of February 17, 2020 by and between Adaptimmune Limited and Gavin Wood (Filed With SEC on February 18, 2020)

Underwriting Agreement, dated January 22, 2020, by and between Adaptimmune Therapeutics plc and Cowen and Company, LLC, as representative of the several Underwriters named therein (Filed With SEC on January 22, 2020)

Senior Vice President Severance Policy dated December 4, 2019 (Filed With SEC on January 13, 2020)

Employment Agreement dated as of January 13, 2020 by and between Adaptimmune, LLC and Elliot Norry (Filed With SEC on January 13, 2020)

Agreement dated as of September 30, 2019 by and between La Fosse Associates Limited and Adaptimmune, LLC (Filed With SEC on November 6, 2019)

Agreement dated as of September 30, 2019 by and between La Fosse Associates Limited, GAR-1 Business Advisory Services and Adaptimmune, LLC (Filed With SEC on November 6, 2019)

Collaboration Agreement dated as of August 26, 2019 by and among Adaptimmune Limited and Noile-Immune Biotech, Inc (Filed With SEC on August 27, 2019)

Collaboration Agreement dated May 14, 2019 between Adaptimmune Limited and AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc (Filed With SEC on August 1, 2019)

Employment Agreement dated as of August 1, 2019 by and between Adaptimmune, LLC and John Lunger (Filed With SEC on August 1, 2019)

James Noble Letter Agreement dated June 26, 2019 (Filed With SEC on June 27, 2019)

James Noble Variation Agreement dated June 26, 2019 (Filed With SEC on June 27, 2019)

Employment Agreement dated as of June 26, 2019 by and between Adaptimmune, LLC and Adrian Rawcliffe (Filed With SEC on June 27, 2019)

James Noble Letter of Appointment dated June 26, 2019 (Filed With SEC on June 27, 2019)

Purchase Agreement, dated September 5, 2018, between Adaptimmune Therapeutics plc and Matrix Capital Management Master Fund, LP, New Enterprise Associates 16, L.P, New Enterprise... (Filed With SEC on September 5, 2018)

Amendment Agreement No. 6, dated July 20, 2018 between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on August 2, 2018)

Lease, dated February 28, 2018, between MEPC Milton Park No. 1 Limited, MEPC Milton Park No. 2 Limited and Adaptimmune Limited relating to 39 Innovation Drive, Milton Park (Filed With SEC on March 15, 2018)

Collaboration Agreement, dated January 5, 2018, between Adaptimmune Limited and Cell Therapy Catapult Limited (Filed With SEC on March 15, 2018)

Rules of the Adaptimmune Therapeutics plc 2016 Employee Share Option Scheme, dated January 14, 2016, as amended December 18, 2017 (Filed With SEC on March 15, 2018)

Rules of the Adaptimmune Therapeutics plc 2015 Share Option Scheme, dated March 16, 2015, as amended April 15, 2015, January 13, 2016 and December 18, 2017 (Filed With SEC on March 15, 2018)

First Amendment to Employment Agreement, dated January 12, 2018 and effective October 30, 2017, between Adaptimmune LLC and Gwendolyn Binder-Scholl (Filed With SEC on March 15, 2018)

Rent Security Deposit Deed, dated February 28, 2018, between MEPC Milton Park No. 1 Limited, MEPC Milton Park No. 2 Limited and Adaptimmune Limited relating to 39 Innovation... (Filed With SEC on March 15, 2018)

Amendment Agreement No. 5, dated September 7, 2017 between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on November 2, 2017)

ADAPTIMMUNE THERAPEUTICS PLC (a public limited company organized under the laws of England and Wales) 7,000,000 American Depositary Shares Representing an Aggregate of 42,000,000... (Filed With SEC on April 5, 2017)

ADAPTIMMUNE THERAPEUTICS PLC (a public limited company organized under the laws of England and Wales) 14,300,000 American Depositary Shares Representing an Aggregate of 85,800,000... (Filed With SEC on March 22, 2017)

CO-DEVELOPMENT AND CO-COMMERCIALISATION AGREEMENT BETWEEN ADAPTIMMUNE LIMITED AND BELLICUM PHARMACEUTICALS, INC. (Filed With SEC on March 13, 2017)

EXECUTIVE SEVERANCE POLICY (Filed With SEC on March 13, 2017)

DATED 10 March 2017 (1) ADAPTIMMUNE THERAPEUTICS PLC and (2) J.J. NOBLE SERVICE AGREEMENT (Filed With SEC on March 13, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 13, 2017)

Adaptimmune Therapeutics plc, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom T: +44 (0)1235 430000 www.adaptimmune.com Registered in England no:... (Filed With SEC on November 10, 2016)

CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between Merck Sharp & Dohme B.V., and Adaptimmune Limited Dated: October 27th, 2016 (Filed With SEC on November 10, 2016)

PRESCRIBED CLAUSES (Filed With SEC on November 10, 2016)

STRATEGIC ALLIANCE AGREEMENT (Filed With SEC on November 10, 2016)

SERVICES AGREEMENT (Filed With SEC on November 10, 2016)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2016)

Adaptimmune Therapeutics plc, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom T: +44 (0)1235 430000 www.adaptimmune.com Registered in England no:... (Filed With SEC on November 10, 2016)

Adaptimmune Therapeutics plc, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom T: +44 (0)1235 430000 www.adaptimmune.com Registered in England no:... (Filed With SEC on August 12, 2016)

Adaptimmune Therapeutics PLC (68)